Feb 2009 Joined KPMG Apr 2010 Joined JPMorgan Chase & Co. Sep 2017 Head of Corporate Communications, the Company Jun 2018 Interim CFO, the Company Director, Sosei R&D Ltd. Nov 2018 Executive Vice President and CFO, the Company Jan 2019 Director, Heptares Therapeutics Ltd. (currently Nxera Pharma UK Limited) (current) Apr 2021 Executive Officer, COO and CFO, the Company Sep 2021 Executive Officer, CFO, the Company Mar 2022 Director and Representative Executive Officer, President and CEO, the Company Aug 2022 Director, Sosei Group USA Inc. (currently Nxera Pharma USA Inc.) (current) Apr 2023 Representative Director, President, Sosei Co., Ltd. Jul 2023 Director, Idorsia Pharmaceuticals Japan Ltd. (currently Nxera Pharma Japan Ltd.) Sep 2024 Representative Director, Nxera Pharma Japan Ltd. Mar 2025 Chairman of the Board and Representative Executive Officer, President and CEO, the Company (current) Jul 2025 Director, Nxera Pharma Japan Ltd. (current)

Apr 1991 Clinical Practice, St George's and St Bartholomew's Hospital Jun 1997 Head of Anti-Infectives, Bayer Pharma AG Jun 2008 Senior Vice President, Head of Research, Site Head, Chief Medical Officer, R&D Europe, Pfizer Inc. Apr 2011 Chief Medical Officer, Creabilis Sep 2013 Honorary Professor, School of Medicine, Swansea University (current) Feb 2014 COO, The Francis Crick Institute Jun 2015 Honorary Professor, Translational Medicine, St George's Hospital Medical School (current) Feb 2017 Chair, Scientific Translation, The Francis Crick Institute (current) President, R&D, Summit Therapeutics Jun 2018 Outside Director, the Company (current) Mar 2020 COO and CEO, JuvRX Division, Juvenescence Ltd. Apr 2022 CEO, Relation Therapeutics Limited (current) Chair of the Board, Centauri Therapeutics Limited (current)

Jan 1988 Joined PricewaterhouseCoopers Dec 2000 Corporate Finance Director, Cable & Wireless plc. Jun 2002 Outside Director, MobileOne Ltd. (currently M1 Ltd.) Jan 2004 Divisional Finance Director, Cobham plc. Aug 2007 Chief Financial Officer, Protherics plc. (currently BTG plc.) Dec 2008 Chief Financial Officer, BTG plc. Jul 2019 Senior Independent Director, Ergomed plc. Mar 2020 Outside Director, the Company (current) Sep 2020 Non-Executive Director, BioPharma Credit plc. (current) Jul 2021 Chief Financial Officer, Syncona Investment Management Limited Apr 2024 Executive Partner, Syncona Investment Management Limited

Apr 1984 Joined Eisai Co., Ltd. Sep 1994 Joined IBRD K.K. Sep 1999 Joined Monsanto K.K. (currently Pfizer Japan Inc.) Nov 2000 Joined AstraZeneca K.K. Sep 2006 Joined Pfizer Japan Inc. Apr 2007 Joined Bristol-Myers Squibb K.K. Nov 2017 Vice President, Japan, Korea, Taiwan and Intercontinental (Australia, Brazil, Turkey, India, Middle East, South America, etc.), Global Regulatory Sciences Intercontinental, Bristol-Myers Squibb Mar 2020 Vice President, Intercontinental (China, Korea, Taiwan, Australia, Russia, Brazil, Turkey, India, Middle East, South America, etc.), Global Regulatory Sciences Intercontinental, Bristol-Myers Squibb Apr 2023 Outside Director, the Company (current)

Apr 1999 Registered as Attorney-at-Law; joined Nishimura & Partners (currently Nishimura & Asahi) Sep 2004 Worked at Debevoise & Plimpton LLP, New York Apr 2005 Admitted to the New York State Bar Jan 2008 Partner, Nishimura & Asahi (current) Sep 2008 Part-time Lecturer, Hitotsubashi University Graduate School of International Corporate Strategy May 2016 Outside Audit and Supervisory Board Member, Tabikobo Co., Ltd. Jun 2018 Outside Director, MIXI, Inc. Sep 2018 Part-time Lecturer, Business Law Program, Hitotsubashi University Graduate School of Law (current) Jun 2019 Outside Audit and Supervisory Board Member, Nippon Signal Co., Ltd. Jun 2023 Outside Director, Tsukishima Holdings Co., Ltd. (current) Mar 2025 Outside Director, the Company (current)

Sep 1998 Trainee Solicitor, Charles Russell LLP Jan 2000 Associate, Linklaters LLP May 2010 Partner, Head of Employment, Linklaters LLP (current) Jan 2014 Global Head of Employment and Incentives (Global Executive Member), Linklaters LLP Mar 2021 Senior Independent Director; Board, Nomination, Audit and Risk and Remuneration Committee Member, Kent FA (current) May 2022 Governor and Trustee; Board, Finance and Estates Committee, and Strategy, Appointments and Remuneration Committee Member, Royal Russell School (current) Nov 2022 Non-Executive Director; Board, Nomination, Remuneration and Audit Committee Member, ZIGUP plc. (current) Mar 2025 Outside Director, the Company (current)

Apr 1994 Registered as Physician; joined Department of Plastic Surgery, Kyoto University Apr 1998 Joined Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare) Jan 2002 Medical Officer, WHO Headquarters, Geneva, etc. Jan 2007 Director of Medical Administration and Professor, Graduate School, International University of Health and Welfare; Director of Administration, Mita Hospital, etc. Feb 2010 Vice President, Government Affairs, etc., Covidien Japan K.K. Jul 2015 Executive Officer, Head of Medical Policy, Chief of President's Office, etc., MSD K.K. Oct 2018 Executive Director (currently Director), Japan Medical Isotope Development Preparatory Organization (current) Apr 2019 Founder, Representative Director and President, Japan Medical Isotope Technology Development Co., Ltd. (current) Jul 2019 Co-founder, Special Advisor, Fusionea RI Technologies Co., Ltd. (current) Jan 2020 Co-founder, Representative Director and President, Japan Medical Isotope Co., Ltd. (current) Jan 2021 Founder, Representative Partner (currently Representative Director and President), PH Consulting LLC (currently PH Consulting Co., Ltd.) (current) Oct 2021 Co-founder, Executive Officer, CSO, etc., Hedgehog Medtech Inc. (current) Dec 2021 Chairman, European Federation of Pharmaceutical Industries and Associations Japan (EFPIA Japan) Dec 2024 Advisor, MeDiCU Inc. (current) Apr 2025 Member, Strategic Advisory Committee, the Company Mar 2026 Outside Director, the Company (current)